Product Information
TELMISARTAN-AMLODIPINE 40-10 is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $2.8797 per EA under NDC 00378107693. Its NADAC has been published 181 times since Apr 19, 2023.
FDA first approved this application on Aug 26, 2014.
Strength
10; 40 mg/1; mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378107693
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
AMLODIPINE BESYLATE; TELMISARTANApproval Type
Generic (ANDA)
FDA Application
ANDA202516FDA Approved
8/26/2014
On Market Since
9/19/2014
Pharmacological Classes
Price Statistics
The NADAC for TELMISARTAN-AMLODIPINE 40-10 has been published 181 times since Apr 19, 2023, and over the history we have for it it has declined 22.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.8797 per EA |
|---|---|
| All-time high | $3.7199 (May 10, 2023) |
| All-time low | $1.9666 (Aug 21, 2024) |
| 52-week high | $3.0465 |
| 52-week low | $2.4859 |
| Median price | $2.4488 |
| Average price | $2.5483 |
| Largest weekly change | -37.5% (May 17, 2023) |
| Weeks tracked | 181 |
| Tracking since | Apr 19, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the telmisartan and amlodipine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
telmisartan and amlodipine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TELMISARTAN-AMLODIPINE 40-10?
The current National Average Drug Acquisition Cost (NADAC) for TELMISARTAN-AMLODIPINE 40-10, manufactured by Mylan Pharmaceuticals Inc., is $2.8797 per EA (NDC 00378107693), effective Sep 30, 2026.
How has the price of TELMISARTAN-AMLODIPINE 40-10 changed over time?
Over the history we have for it, the NADAC for TELMISARTAN-AMLODIPINE 40-10 has declined 22.6%. It has been tracked across 181 weekly CMS publications since Apr 19, 2023.
What are the highest and lowest recorded NADAC prices for TELMISARTAN-AMLODIPINE 40-10?
Since Apr 19, 2023, the NADAC for TELMISARTAN-AMLODIPINE 40-10 has ranged from a low of $1.9666 (Aug 21, 2024) to a high of $3.7199 (May 10, 2023), with a median of $2.4488 per EA.
Are there cheaper alternatives to TELMISARTAN-AMLODIPINE 40-10?
No other NADAC-published product currently shares the active ingredient and strength of TELMISARTAN-AMLODIPINE 40-10 in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures TELMISARTAN-AMLODIPINE 40-10?
TELMISARTAN-AMLODIPINE 40-10 (NDC 00378107693) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.